摘要
目的观察前列腺素E1(PGE1)间歇性疗法治疗糖尿病肾病(DN)的临床疗效。方法采用前瞻对照研究方法,入选患者随机分为治疗组和对照组。治疗组给予前列腺素E1间歇性疗法给药(每日2次,每次10μg,每月7天,共3个月),对照组给予前列腺素E1单疗程给药(每日2次,每次10μg,连续用药20天)。观察两组治疗前后24小时尿蛋白、24小时尿微量白蛋白、尿白蛋白肌酐比值(UACR)等一系列指标的变化。结果与对照组相比,治疗组患者在24小时尿蛋白定量(2.9±0.5)g vs(3.9±0.8)g、尿24小时微量白蛋白定量(2.1±0.5)g vs(2.6±0.5)g、尿N-乙酰-β-D氨基葡萄糖苷酶(16±3)U/L vs(21±4)U/L、尿视黄醇结合蛋白(51±17.4)g vs(66±12.8)g和尿β2-微球蛋白(1.8±0.4)g vs(2.8±0.6)g均显著降低(P<0.05)。结论前列腺素E1间歇性疗法能够减轻糖尿病患者肾损伤的进展,较单疗程给药具有更好的糖尿病肾保护作用。
Objective To study the effect of intermittent therapy of using prostaglandin E1 （PGE1） on treatment of diabetic kidney disease （DKD）. Methods The study was designed as a prospective and randomized research. All patients with DKD were randomly divided into two groups, treatment group and control group. The patients of treatment group were administrated with PGE1 through intermittent therapy （10μg/time, twice a day, 7 days per month,totally 3 months）. Those of control group received single-course PGE1 （10 μg/time, twice a day, 14 days consecutively）. All patients were observed 24 h urine protein, 24 h urinary albumin, NAG, β2-MG and so on. Results Compared with those in control group, there were significant decrease in treatment group in 24 h urine protein,24 h urinary albumin（2.9±0.5） g vs （3.9±0.8） g,NAG（16±3） U/L vs （21±4） U/L,132-MG（1. 8±0. 4） g vs （2.8±0.6） g, RBP（51±17.4） g vs （66±12.8） g after PGE1 treatment（P 〈0.05）. Conclusion The study showed that intermittent therapy of PGE1 would better protect patients with DKD from renal injury than single-course treatment using PGE1.
出处
《临床荟萃》
CAS
2013年第12期1340-1342,共3页
Clinical Focus
关键词
糖尿病肾病
前列腺素E类
前瞻性研究
diabetic nephropathies
prostaglandins E
prospective studies
作者简介
通信作者：陆学胜，Email：lxssh@126．com
